Focus: ZOLL is a 5,000+ employee medical device company headquartered in San Jose, CA, specializing in defibrillators, resuscitation systems, and temperature management devices for cardiovascular, neurological, and respiratory emergencies. Founded in 1980, it operates as an established player in acute care and sudden cardiac death prevention.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
Hot — 150 jobs added in 30d
Net +26 (150 new, 124 removed). Aggressive expansion phase.
Recent layoff filing — 96 affected
Source: state DOL filings via Big Local News
ZOLL offers stability and growth in a mature device company with strong commercial expansion, but prospective R&D and clinical-track candidates should note the thin pipeline and recent layoff signal.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Zoll
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Zoll's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Imaging-Based FFR on Par With Wire for PCI Outcomes - MedPage Today
Imaging-Based FFR on Par With Wire for PCI Outcomes MedPage Today
Multimechanism Heart Failure Treatment for Post- hospitalized HFpEF and HFmrEF Patients - Medscape
Multimechanism Heart Failure Treatment for Post- hospitalized HFpEF and HFmrEF Patients Medscape
Sudden Cardiac Death Risk and Heart Failure Management at ACC.26 – How ZOLL Innovations Redefine Protection - PharmiWeb.com
Sudden Cardiac Death Risk and Heart Failure Management at ACC.26 – How ZOLL Innovations Redefine Protection PharmiWeb.com
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Source: state DOL filings, aggregated via Big Local News
Single WARN filing affecting ~96 employees represents ~2% of workforce; isolated event rather than systemic restructuring, but candidates should monitor announcements for additional facility actions.
Recent peer-reviewed publications with author affiliations at this company
Changes in quality of life in patients with atrial fibrillation and central sleep apnea treated with transvenous phrenic nerve stimulation.
The impact of defibrillation current and pad position on return of spontaneous circulation during refractory ventricular fibrillation.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo